secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMMUNIC, INC. (IMUX)
CIK:        0001280776
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0001193805-24-000605
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunic reports Q1 2024 net loss $29.6M; cash extended into Q3 2025 on $240M private placement
--------------------------------------------------------------------------------

- Net loss $29.6M ($0.30/share) vs $25.3M ($0.58) in Q1 2023; R&D spend $18.7M, down 18% YoY.
- Cash $97.3M at March 31, 2024; runway into Q3 2025 after $240M private placement ($80M initial tranche).
- Phase 2 CALLIPER (progressive MS) top-line data expected April 2025; Phase 3 ENSURE readout Q2 2026 and H2 2026.
- Received fourth US patent for vidofludimus calcium (composition of matter) protecting into 2041.
- IMU-856 preparing for phase 2 in celiac disease after positive phase 1b data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1280776/000119380524000605/0001193805-24-000605-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1280776/000119380524000605/e663589_8k-immunic.htm
  HTML page:      https://secwatch.observer/filing/0001193805-24-000605

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer